Lilly Asia Ventures had contributed to cancer diagnostics technology provider Burning Rock's series C round, which was led by GIC.

Novartis and Johnson & Johnson have contributed to a series A round for Vor Biopharma, an oncology drug developer co-founded by PureTech Health.

Samsung Next and GreatPoint Ventures supplied series A capital for emergency response software provider RapidDeploy, which recently moved from South Africa to the US.

Lilly Asia Ventures has secured a $40m commitment for its fifth biosciences fund, LAV Biosciences V, from San Francisco’s city and county pension fund.

Ascletis has led new strategic partner 3-V Biosciences' $18m series E round, which included existing investors New Enterprise Associates and Kleiner Perkins.

Spun out of Inesc Tec under a strategic agreement with Frontier IP, Insignals hopes to commercialise a surgical guidance device for brain implants to treat conditions including Parkinson's.

David Schenkein is GV's latest general partner and will focus on life sciences while retaining a chairman position at oncology therapy developer Agios Pharmaceuticals.

The corporate venturing units of Semapa and KPN have contributed to Armilar's TechTransfer Fund, which has raised almost $51m on its way to a target of about $68m.

Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.

Kaust is preparing for the third phase of its Taqadam startup accelerator, which is supported by a host of Saudi Arabian academic institutions and claims to have achieved a 35% female participation rate.